{"id":"dupilumab-step-down","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Injection site reactions"},{"rate":"10-15","effect":"Conjunctivitis"},{"rate":"5-10","effect":"Headache"},{"rate":"5-10","effect":"Oropharyngeal pain"},{"rate":"5-10","effect":"Upper respiratory tract infection"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Dupilumab binds to IL-4 receptor alpha, a shared component of IL-4 and IL-13 signaling pathways that drive type 2 inflammation. By blocking this receptor, it suppresses the production of IgE and other inflammatory mediators involved in allergic and atopic diseases. The 'step-down' designation refers to dose reduction or discontinuation protocols in clinical practice after disease control is achieved.","oneSentence":"Dupilumab is a monoclonal antibody that blocks the IL-4 receptor alpha subunit, inhibiting IL-4 and IL-13 signaling to reduce type 2 inflammatory responses.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:45:09.725Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate-to-severe atopic dermatitis"},{"name":"Moderate-to-severe asthma with type 2 inflammation"},{"name":"Chronic rhinosinusitis with nasal polyps"},{"name":"Eosinophilic esophagitis"}]},"trialDetails":[{"nctId":"NCT05642208","phase":"PHASE4","title":"Dupilumab Step-down Strategy to Maintain Remission in Adult and Adolescents Patients With Atopic Dermatitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Nantes University Hospital","startDate":"2023-03-08","conditions":"Atopic Dermatitis, Eczema, Atopic","enrollment":256}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Dupilumab step-down","genericName":"Dupilumab step-down","companyName":"Nantes University Hospital","companyId":"nantes-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Dupilumab is a monoclonal antibody that blocks the IL-4 receptor alpha subunit, inhibiting IL-4 and IL-13 signaling to reduce type 2 inflammatory responses. Used for Moderate-to-severe atopic dermatitis, Moderate-to-severe asthma with type 2 inflammation, Chronic rhinosinusitis with nasal polyps.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}